About Advanced Micro Devices, Inc. - Common Stock (AMD)
Advanced Micro Devices is a leading global semiconductor company that designs and manufactures computing and graphics solutions for a wide range of applications. The company is known for its innovative microprocessors, graphics cards, and system-on-chip products, which are used in personal computers, servers, and embedded systems. AMD focuses on high-performance computing, gaming, and data center markets, offering advanced technologies that compete with those of other major players in the industry. By delivering cutting-edge products that push the boundaries of processing power and efficiency, AMD plays a critical role in driving technological advancements and enhancing user experiences across various platforms. Read More
Hello, Reader. In the 1989 film Field of Dreams, the famous line goes: “If you build it, they will come.” But in the AI boom, the saying may need an update: “If you build it, communities will protest. But if you have already built it, they may come.” The “it” here is data centers. As AI…
Truist Securities upgraded Best Buy to Buy with a $95 price target, citing rising sales of AI-enabled gadgets ahead of the retailer's earnings report due later this month.
Investors looking to make the most of the AI-driven chip boom will do well to take a closer look at this foundry giant before it doubles over the next three years.
AI spending continues reshaping technology as Nvidia, AMD, Cisco, Intel and semiconductor companies announce new investments, partnerships and infrastructure initiatives.
What Happened? Shares of computer processor maker AMD (NASDAQ:AMD) jumped 5.1% in the afternoon session after the company priced a $4.75 billion bond offerin...
What Happened? Shares of semiconductor company Semtech (NASDAQ:SMTC) jumped 3.5% in the afternoon session after Needham maintained its 'Buy' rating and $200 ...
NVIDIA lines up over $500 billion in third-party capital, backed by BlackRock, Apollo, Brookfield, and Goldman Sachs, to finance AI GPU capacity through securitized loans.
Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United
Cerebras shares fell after Q2 results, but strong RPO growth past $25 billion, analyst Moderate Buy ratings, and expanding inference demand suggest the pullback may be overdone.
